Analysts initiate coverage on Alumis and Enliven with bullish ratings

benzinga.com October 31, 2024, 04:01 PM UTC

Summary: Baird analyst Brian Skorney has started coverage on Alumis Inc. with an Outperform rating and a price target of $25. The stock closed at $11.23 on Wednesday.

Jones Trading analyst Soumit Roy also initiated coverage on Enliven Therapeutics with a Buy rating and a price target of $36, while the stock closed at $28.39.

Other analysts began coverage on Intensity Therapeutics, Terns Pharmaceuticals, and Braze, with varying ratings and price targets reflecting their current stock prices.

Source

Article metrics
Significance3.5
Scale & Impact3.9
Positivity5.6
Credibility7.5

What is this?

This is article metrics. Combined, they form a significance score, that indicates how important the news is on a scale from 0 to 10.

My algorithm scores 10,000 news articles daily, and creates a single significance-ordered list of news.

Read more about how I calculate significance, or see today's top ranked news on the main page:

See today's news rankings